1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Cathepsin
  4. Cathepsin C Isoform

Cathepsin C

 
Cat. No. Product Name Effect Purity
  • HY-100227
    E 64c
    Inhibitor 99.32%
    E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.
  • HY-112318A
    GSK-2793660
    Inhibitor 99.91%
    GSK-2793660 is an orally active and irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 can be used for the research of bronchiectasis.
  • HY-P2922
    Cathepsin C
    Cathepsin C is a lysosomal cysteine protease essential for catalytic activation of many serine proteases, including proteinase 3 (PR3), neutrophil elastase (NE), cathepsin G (CTSG), granzyme A/B/C, and mast cell chymase.
  • HY-112318
    GSK-2793660 free base
    Inhibitor
    GSK-2793660 (free base) is an oral, irreversible inhibitor of Cathepsin C (CTSC). GSK-2793660 (free base) can be used for the research of bronchiectasis.
  • HY-P5898
    Z-Val-Val-Nle-diazomethylketone
    Inhibitor
    Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research.
  • HY-180799
    Cathepsin L-IN-6
    Inhibitor
    Cathepsin L-IN-6 (Compound 6a) is a selective cathepsin L inhibitor with an IC50 of 0.021 μM. Cathepsin L-IN-6 suppresses cathepsin L activity by directly binding to cathepsin L. Cathepsin L-IN-6 inhibits IL-6 and IL-8. Cathepsin L-IN-6 shows a high anti-inflammatory activity. Cathepsin L-IN-6 can be used in the research of acute lung injury.
  • HY-177408
    Cathepsin C-IN-7
    Inhibitor
    Cathepsin C-IN-7 (Page 68) is a Cathepsin C inhibitor. Cathepsin C-IN-7 can be used in research related to primary cancers and cancer metastases.
  • HY-146581
    Cathepsin C-IN-4
    Inhibitor
    Cathepsin C-IN-4 (compound SF27) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 65.6 nM. Cathepsin C-IN-4 also inhibits THP-1 and U937 cell, with IC50 values of 203.4 and 177.6 nM, respectively.
  • HY-146580
    Cathepsin C-IN-3
    Inhibitor
    Cathepsin C-IN-3 (compound SF11) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 61.79 nM. Cathepsin C-IN-3 also inhibits THP-1 and U937 cell, with IC50 values of 101.5 and 86.5 nM, respectively.
  • HY-171888
    BI-9740
    Inhibitor
    BI-9740 is an orally active and selective cathepsin C (CatC) inhibitor, with an IC50 of 0.6 nM in mice and 2.6 nM in rats. BI-9740 can inhibit the production of active neutrophil elastase. Additionally, BI-9740 is capable of reducing the activities of neutrophil elastase and cathepsin G in the bone marrow of rats, alleviating pathological damage to grafts after heart transplantation, shortening the reperfusion time, and improving left ventricular function. BI-9740 can be used in research related to organ transplantation.
  • HY-172242
    Verducatib
    Inhibitor 98.94%
    Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential.
Cat. No. Product Name / Synonyms Species Source